Department of Medical Oncology, Comprehensive Cancer Centre F. Baclesse, UNICANCER, Caen, France.
Department of Bio-Pathology, Comprehensive Cancer Centre F. Baclesse, UNICANCER, Caen, France.
BMC Cancer. 2024 Oct 29;24(1):1328. doi: 10.1186/s12885-024-13065-0.
Further research is still needed to fully understand the potential of prostate-specific membrane antigen (PSMA) in breast cancer (BC) and to develop and optimize targeted therapies and imaging modalities. The objective of this study was to present a comprehensive analysis of immunohistochemistry data on PSMA staining in BC and to discuss its potential value in a theranostic approach.
Fifty-eight male and female patients were randomly selected from a retrospective database of patients who underwent surgery for breast cancer between January 2012 and December 2017 and for whom a specimen is available in our tumour library. Immunodetection of PSMA and CD31 was performed on serial slides. The digitized slides were reviewed and analysed by an experienced pathologist. Additionally, the corresponding TIFF images were processed to calculate the percentage of positive neovessels.
Eighteen patients (31.6%) had no expression, 29 (50.9%) had PSMA neovascular expression scored as "1", and 10 (17.5%) had neovascular expression scored as "2". Digital immunohistochemistry analysis for this last specific group of patients showed a median proportion of positive neovessels equal to 5% (range: 3-19). A multivariable logistic regression demonstrated that the odds of PSMA positivity were 4.55 times higher in non-luminal tumours and decreased by a factor of 0.12 in lobular subtypes. There was no association between sex or the presence of a germline BRCA1/2 mutation and PSMA expression in tumours.
Our study highlights generally low neovascular expression of PSMA in specific histopathological subtypes of breast cancer, which will likely hamper the development of an adequate theranostic strategy.
The procedure has been retrospectively registered to the French National Institute for Health Data (N° F20220615153900).
为了充分了解前列腺特异性膜抗原（PSMA）在乳腺癌（BC）中的潜力，并开发和优化靶向治疗和成像方式，仍需要进一步研究。本研究的目的是对 BC 中 PSMA 染色的免疫组织化学数据进行全面分析，并讨论其在治疗方法中的潜在价值。
从 2012 年 1 月至 2017 年 12 月期间接受乳腺癌手术且肿瘤库中保存有标本的回顾性患者数据库中随机选择 58 名男性和女性患者。对 PSMA 和 CD31 进行免疫检测。由一位经验丰富的病理学家对数字化切片进行审查和分析。此外，还处理了相应的 TIFF 图像以计算阳性新生血管的百分比。
18 名患者（31.6%）无表达，29 名患者（50.9%）PSMA 新生血管表达评分“1”，10 名患者（17.5%）PSMA 新生血管表达评分“2”。对最后一组特定患者的数字免疫组织化学分析显示，阳性新生血管的中位数比例等于 5%（范围：3-19）。多变量逻辑回归表明，非腔型肿瘤中 PSMA 阳性的可能性高 4.55 倍，而在小叶型亚型中则降低了 0.12 倍。在肿瘤中，PSMA 表达与性别或是否存在种系 BRCA1/2 突变之间没有关联。
我们的研究强调了在乳腺癌的特定组织病理学亚型中 PSMA 新生血管表达普遍较低，这可能会阻碍适当治疗策略的发展。
该程序已在法国国家健康数据研究所（N° F20220615153900）进行了回顾性注册。
